Pharmaceutical analyst Jo Walton brings her expertise to Foundation’s Supervisory Board

Throughout her 40 years as a pharamaceutical analyst, Jo Walton covered major European and international pharmaceutical and biotechnology companies, providing comparative analyses on the industry’s largest and most influential players. Her expert commentary has been featured in major outlets including BBC, the New York Times and the Financial Times. 

Since the first iteration was published in 2008, Jo has used the Foundation’s Access to Medicine Index reports to inform her insights on market dynamics, investment trends, research and development, shifting pricing dynamics and M&A activity.  

On how the Index drives change within the industry, she says: “The Access to Medicine Index provides a unique and valuable insight into the importance of health equity in publicly traded companies. A strong score in the Index can benefit industry players, as well as patients in low- and middle-income countries, by helping to attract strong staff and reinforce good business practices.” 

In joining the Foundation’s Supervisory Board, Jo hopes to help maximise awareness of the Foundation’s work and its relevance to pharmaceutical companies and investors. 

Jo graduated from Cambridge University with a degree in Natural Sciences and a Post Graduate Certificate in Education in 1982. Before retiring in the summer of 2025, Jo worked for Lehman Brothers, Credit Suisse and UBS.